Why this exists.

What this is — and what it isn't.

Speak Peptides is an editorial reference catalogue covering 25 of the most-discussed peptides — from the FDA-approved (Ozempic, Wegovy, Zepbound, Mounjaro, Tesamorelin) to the research-only gray market (BPC-157, MT-2, Epitalon) and everything in between. Each entry covers what the peptide is, how it works, what it's used for, what's known about safety, what its current regulatory status is, and where the evidence comes from.

It is, very deliberately, not:

• A vendor. We don't sell peptides, we don't take affiliate commissions from anyone who does, and we don't recommend specific sellers anywhere on the site.
• Medical advice. Nothing here tells you what to do with your body. The whole site is built so you can have a more informed conversation with a doctor — not skip having that conversation.
• A forum, a community, or a peptide protocol exchange. There are good versions of those. This isn't one.
• Finished. The page is dated 2026 v1 for a reason: the regulatory landscape (especially around FDA peptide compounding rules) is moving fast. We update accordingly.

How a peptide entry is written.

Every catalogue entry follows the same process:

• Primary sources first. FDA approval letters and labels (via DailyMed), pivotal Phase 3 trials (NEJM, JAMA, Lancet), regulatory authority warnings (FDA, MHRA, TGA, EMA), and PubMed-indexed peer-reviewed reviews. Each entry's "Sources" block links these directly so the reader can verify.
• Plain language pass. Mechanism is rewritten so a curious adult without a biology background can follow. Metaphors are used carefully (peptides as "text messages" between cells, for instance) and kept consistent across the catalogue.
• Safety profile. Where a peptide has known contraindications, boxed warnings, or documented adverse events, those appear in their own clearly-marked block — not buried at the bottom or omitted.
• Regulatory status — current as of the review date. The FDA's Bulk Drug Substances list and PCAC review schedule have moved several times in 2024–2026. Each entry's regulatory note reflects the state at last review.

Drafts are read against the source documents one more time before publish. The standard we hold ourselves to is: could a sophisticated reader (an MD, an endocrinology PA, a longevity-focused biohacker) read this entry without finding an obvious error? When we don't meet that bar, we revise.

Who's behind this.

Editorial team

Speak Peptides is researched and written by a small editorial team. We're not clinicians, and we don't pretend to be. What we are: people who have spent serious time reading the primary literature, talking with physicians and pharmacists who actually work with these compounds, and trying to translate what we found into something a smart adult can read in fifteen minutes without losing the substance. Every entry in the catalogue has been read against its sources at least twice; every regulatory note has been cross-checked against current FDA records.

For now, the editorial team is anonymous — the project is small and the people involved have day jobs. That decision is under continuous review. Once we have a named medical reviewer in place (see below), we plan to put names on the work as well.

Medical reviewer

This v1 release is editorial — meaning the catalogue has been researched against primary sources, but has not been signed off by a named medical reviewer. We are actively seeking a clinician (MD, PA, or pharmacist with peptide-relevant experience) to formally review the catalogue before v1.1. If that's you, or you can introduce us, please write.

Outside contributors

None to date. As we add specialised content (e.g., the GLP-1 comparison work, the access-tier guide), we may engage subject-matter contributors and will credit them inline.

How this is funded.

Speak Peptides is currently self-funded by the editor. Server costs are minimal; the time invested isn't compensated. We don't run display advertising, we don't take affiliate commissions from peptide vendors, telehealth providers, or compounding pharmacies, and we don't accept paid placement of any kind.

If we ever monetise, it will be through one of two transparent paths:

• A paid newsletter or membership covering peptide regulatory updates, comparison briefs, and review of new clinical readouts. The reference catalogue itself stays free and ad-free.
• Clearly-labelled sponsorships — e.g., "this comparison briefing is sponsored by [X]" — with the same separation between editorial and commercial content that any reputable publication maintains. Vendor selection would be vetted, and we would never accept sponsorship from a vendor whose product appears in the catalogue.

If either of those changes the way the catalogue is written, this page will say so explicitly and the change will be dated.

How often this is updated.

Each peptide entry shows a "Last reviewed" date in its modal footer. Our standard cadence is:

• Quarterly — full re-review of all 25 entries against current sources, regulatory status, and any new clinical readouts.
• Within 7 days of a material change — new FDA approval, FDA enforcement action, PCAC vote, or major journal publication relevant to a catalogued peptide. Examples to date: the FDA's December 2024 Tirzepatide OSA approval and the April 2026 removal of twelve peptides from FDA Category 2 are reflected in current entries.
• On reader correction — if a reader flags an error, we re-review immediately and update the entry, with the correction logged.

Corrections.

If you find an error — a misstated fact, an outdated regulatory note, a missing safety caveat, a dead link to a source — please write us. We treat corrections seriously: each one triggers a re-read of the affected entry against current sources, the entry is updated, and the change is logged with the date.

Please write to [email protected] with the entry name and the specific issue. We aim to respond within 5 business days.

What we don't cover (yet).

The 2026 v1 catalogue covers 25 peptides we judged most-searched and most-discussed by the consumer audience. We do not yet cover — though we may in v2:

• Peptide hormones (insulin, GH analogues like Sermorelin, Hexarelin, MK-677/Ibutamoren) beyond what's in the existing catalogue.
• Peptide vaccines (mRNA platforms, peptide-based oncology vaccines).
• Bioactive peptides from food (collagen peptides, casein-derived bioactives) — meaningfully different category, separate guide warranted.
• Cyclic peptide drugs (cyclosporine, vancomycin) — not the consumer-research category this catalogue is built for.

If there's a peptide you'd like added, write us. Demand from readers is the main signal we use to prioritise.